Edward A. Sturchio – Immatics Biotechnologies

GC makes a science of advising biotech companies

Edward Sturchio doesn’t spend his time in a lab like the researchers, technicians and scientists responsible for the life-saving innovations developed by the biotechnology companies he works for. But he has made a science of advising and growing those companies.

Edward A. Sturchio – Immatics Biotechnologies

Edward A. Sturchio | General Counsel and Corporate Secretary | Immatics Biotechnologies

As he chatted with Vanguard in June 2020, Sturchio was enjoying his second day as the new general counsel and corporate secretary at Immatics N.V. and feeling very much back at home in the industry.

“I’ve always had the deep pharma background, but you rarely find a biotech general counsel who also has my securities and corporate experience,” Sturchio says. “I’m a business lawyer and 99 percent of what I do has nothing to do with practicing law.”

Hard science, strong guidance

Founded in Germany in 2000 as a spinoff from a laboratory at the University of Tübingen, and now listed on the Nasdaq Stock Market, Immatics develops therapies that reprogram the body’s own immune system to detect, target and destroy cancer cells.

The company brings together a breadth of proprietary technologies that can identify true targets in tumor tissues and engineer T cells (the body’s specialized immune surveillance cells) with the right T cell receptor to specifically bind and destroy cancer cells but not healthy cells.

Edward A. Sturchio – Immatics Biotechnologies

Immatics presently has four products in clinical trials as part of the U.S. Food and Drug Administration approval process and has several active clinical trial sites in the U.S. and Europe.

The company’s product pipeline was also the foundation of Immatics’ deal—that Sturchio helped close on July 1—with Arya Sciences Acquisition Corp.

“It’s effectively an IPO through a special purpose acquisition company, which is a listed ‘blank check’ company established by a fund or bank with the major purpose to merge with an already operating private company like Immatics,” Sturchio explains.

Sturchio says his role at Immatics, which garnered $253 million in new investment in the deal, will be to help steward the public company’s cultural transformation process while also helping leadership and the company board understand their responsibilities to investors and how to comply with U.S. securities regulations.

Into legal realms

“I approach companies like an investor,” Sturchio says. “I look for great science, strong leadership, marquee investors and its growth mode.”

He’s no stranger to any of the processes. While he always wants to be part of emerging companies offering innovative approaches to health care and life sciences, he’s recently been part of companies with lead assets that treat both widespread and very rare conditions and diseases.

Edward A. Sturchio – Immatics Biotechnologies

“Although I don’t profess to know or understand every aspect of it, the science is really fascinating to me,” he adds. “And as the company focuses on getting the drug down the regulatory pathway, everyone’s looking to accomplish the same goal. It’s an energy you can’t replicate in a law firm.”

Before joining Immatics, Sturchio was a senior vice president, general counsel and corporate secretary at Abeona Therapeutics, a publicly traded cell and gene therapy company creating therapies to treat skin conditions and a syndrome that prevents a child’s body from breaking down certain carbohydrates.

Those therapies are also in clinical trials, according to the company website. Though Abeona is addressing some rare health disorders, its work and a chance to pitch in on company growth were the allure for Sturchio.

Making a big deal

The realm of Sturchio’s work with pharma and life science companies includes board matters, securities, M&A, FDA, contract management, IP, commercial and HR matters.

But the juice of it comes in using his expertise in securities law and public company strategy to move organizations ahead, even as it can require some deft explanations to leadership and an employee base more accustomed to the inner workings of a small private company, he says.

Prior to joining Abeona, Sturchio was global general counsel for Advanced Accelerator Applications. There he built a legal team with more than 10 professionals as part of its growth in the complex realm of nuclear medicine.

Founded in Europe in 2002, AAA’s global work includes diagnostic and treatment therapies in nuclear medicine for cancer, cardiovascular and neurological disorders in their early stages.

“All our products were literally radioactive,” Sturchio recalls, which added a layer of complexity to his already broad responsibilities across the company’s 21 sites in 13 countries.

It’s lead product, Lutathera, treats gastroenteropancreatic neuroendocrine tumors, which caused the death of Apple founder Steve Jobs in 2011.

AAA opened its first U.S. manufacturing and distribution site in New Jersey in 2016. It was also raising $172 million in investment capital and attracted the attention of pharma giant Novartis. Sturchio was part of the leadership team that completed the $4 billion buyout in January 2018.

“There were monthslong negotiations,” he says. “But it was about as friendly a deal as you could have asked for on a deal of that size.”

The counsel’s role

That the transactions appeal to Sturchio as much as the science goes a bit against tradition—he’s from a family of surgeons and healthcare practitioners.

Raised in northern New Jersey, Sturchio earned his bachelor’s in psychology from Villanova University in 1997. But he was more interested in law, going on to earn a J.D. as a merit scholar from Seton Hall University in 2000.

After a year clerking for New Jersey Superior Court Justice Francine A. Schott, Sturchio spent the next 15 years at private firms in the New York area.

Edward A. Sturchio – Immatics Biotechnologies

His expertise in corporate securities opened the door at AAA in 2016, and he has been in-house ever since.

Away from the office, Sturchio loves nothing more than a day on the greens. He’s played more than 10,000 rounds of golf with his father, the two having teed it up on renowned courses such as Pebble Beach and Spyglass, he says.

In-house work will continue to be par for the course for him, too. When he talks about the general counsel role, Sturchio draws from the thoughts of Merck CEO Kenneth Frazier who previously served as its general counsel.

“When you slice the cake, the GC has a top down view of every layer of the company and the things going on inside those layers,” Sturchio says. “You have to be the central repository of real time, cross-functional information. You need the ability to be the strategic advisor based on aggregated experiential data while never losing sight of the company’s objectives.”

Published on: July 23, 2020



Showcase your feature on your website with a custom “As Featured in Vanguard” badge that links directly to your article!

Copy and paste this script into your page coding (ideally right before the closing tag) where you want to display our review banner.


It was a great honor to be featured in Vanguard Law. Working with every member of the team, from the initial interview with Erin Clark, through production with Victor Martins, writing the article with Taryn Plumb and creating the final content with Dave Gushee, was a true pleasure. Everyone was very professional, enthusiastic and supportive, and their creative approach and positive attitude clearly came through in the final product.
– Kevin C. Rakowski, Senior Vice President, Deputy General Counsel, Compliance with Radian Group Inc.
The piece highlighting my company, Bob Baker Enterprises, Inc., came out fabulous. Our company is in the new and used car sales and service industry. Everyone was great to work with and extremely professional. They produced a high-quality product and have provided expert assistance and guidance post-production of the article.
– Wade Poulson, General Counsel, Bob Baker Enterprises Inc.
I was honored to be the subject of an article. I enjoy reading Vanguard articles and seeing how other attorneys got to their positions and see their jobs. It's also interesting to see how different law firms partner with the subjects of the articles.
– Henry Marquard, in-house counsel, Stanley Consultants Inc.
As promised in advance, my feature in Vanguard has increased my visibility within the profession and prompted more than a few people I have not communicated with recently to reconnect. One of the Italian law firms I have used in the past is now in the process of interviewing me for an article on their website and tweeting out the feature story. Activity and the number of people connecting with me on LinkedIn has soared, which is great. The Vanguard writers and editorial staff were great to work with—highly professional and made the effort to make the experience both fun and rewarding (they were also respectful of the time pressures and demands all lawyers face). I was very pleased with the experience and the final outcome. Needless to say, I have been very pleased. All in all working with Vanguard has been a very positive experience which generated good publicity for both Shawcor and myself. My sincere thanks.
– Tim Hutzul, General Counsel, ShawCor Ltd.


Summer I 2024



  • * We’ll never share your email or info with anyone.
  • This field is for validation purposes and should be left unchanged.